Seeking Alpha
 

Baxter International Inc (BAX)

- NYSE
  • Wed, Aug. 5, 3:35 PM
    • Baxter International (BAX +4.7%) is up on more than a 4x surge in volume in apparent response to a 13D filing by noted investor Daniel Loeb's Third Point LLC that disclosed a 7% stake of 37,925,000 shares.
    • In a press release, Baxter says that it has "engaged in discussions with Third Point representatives and expects to continue a constructive dialogue." It also says that the Board and management are committed to enhancing value for all Baxter shareholders.
    | Wed, Aug. 5, 3:35 PM | 4 Comments
  • Tue, Aug. 4, 7:46 AM
    • Shire plc (NASDAQ:SHPG) discloses that it made a proposal to Baxter (NYSE:BAX) spin-off Baxalta (NYSE:BXLT) to combine the firms in an all-stock transaction valued at $30B or $45.23 per share. Baxalta had previously declined to enter into discussions with Shire about a potential merger.
    • Update: BXLT up 19% premarket on robust volume. SHPG down 4% on high volume.
    | Tue, Aug. 4, 7:46 AM | 17 Comments
  • Mon, Aug. 3, 9:14 AM
    • Baxalta (BXLT) announces that it published pivotal Phase 3 data for its investigational Von Willebrand treatment BAX 111 in the journal of American Society and Hematology.
    • The data demonstrated that 100% of the patients treated with BAX 111, a highly purified recombinant von Willebrand factor candidate, achieved success in the management of bleeding episodes.
    • BAX 111 is currently under review by FDA. If approved, it would become the first recombinant replacement treatment for managing bleeding episodes for von Willebrand patients. Previously: Baxter's recombinant von Willebrand factor delivers 100% treatment success rate (April 20)
    • Related tickers: (BAX)
    | Mon, Aug. 3, 9:14 AM | Comment!
  • Wed, Jul. 29, 4:41 PM
    • Baxter International (NYSE:BAX) Q2 results ($M): Total Revenues: 3,893 (-8.7%); BioScience: 1,429 (-18.4%); Medical Products: 2,464 (-1.9%).
    • Sales by segment: Hemophilia: 672 (-25.7%); Immunoglobulin Therapies: 422 (-41.4%); Inhibitor Therapies: 183 (-0.5%); BioTherapeutics: 152 (-1.9%); Fluid Systems: 518 (-3.0%); Renal: 949 (-9.1%); Integrated Pharmacy Solutions: 548 (-16.3%); Surgical Care: 333 (-3.8%).
    • Net Income: 332 (-36.2%); EPS: 0.60 (-36.8%).
    • Q3 Guidance: Revenues: flat from (9 - 10%); GAAP EPS: $0.00 - 0.02.
    • H2 Guidance: GAAP EPS: $0.23 - 0.27.
    • Shares are unchanged after hours.
    | Wed, Jul. 29, 4:41 PM | 5 Comments
  • Wed, Jul. 29, 4:35 PM
    • Baxter (NYSE:BAX): Q2 EPS of $1.00 beats by $0.05.
    • Revenue of $3.89B (-6.3% Y/Y) beats by $120M.
    • Shares -0.03%.
    • Press Release
    | Wed, Jul. 29, 4:35 PM | 4 Comments
  • Wed, Jul. 29, 12:26 PM
    • Baxter International (BAX +1.1%) reports Q2 results after the close. Consensus view is EPS of $0.95 on revenues of $3.8B.
    | Wed, Jul. 29, 12:26 PM | Comment!
  • Tue, Jul. 28, 5:35 PM
  • Wed, Jul. 8, 7:53 AM
    • Relypsa (NASDAQ:RLYP) initiated with Buy rating and $42 (29% upside) price target by Cantor Fitzgerald.
    • K2M Holdings (NASDAQ:KTWO) initiated with Buy rating and $30 (24% upside) price target by Needham.
    • Baxter International (NYSE:BAX) downgraded to Market Perform from Outperform by BMO Capital Markets. Price target lowered to $36 (3% downside risk) from $80.
    | Wed, Jul. 8, 7:53 AM | Comment!
  • Tue, Jul. 7, 10:50 AM
    • Edwards Lifesciences (EW -0.8%) upgraded to Overweight from Equal Weight with a $168 (17% upside) price target (up from $135) by Morgan Stanley.
    • HealthSouth (HLS -0.7%) upgraded to Market Outperform from Market Perform with a price target of $54 (15% upside) by JMP Securities.
    • AstraZeneca (AZN -0.6%) upgraded to Buy from Hold with an $81 (25% upside) price target by Berenberg.
    • Humana downgraded to Hold from Buy by Argus Research.
    • Intuitive Surgical (ISRG -1.1%) downgraded to Underweight from Equal Weight by Morgan Stanley. Price target lowered to $500 (6% upside) from $560.
    • Aegerion Pharmaceuticals (AEGR -0.5%) downgraded to Sell from Neutral by Guggenheim Securities.
    • Centene (CNC -3.3%) downgraded to Equal Weight from Overweight by Barclays. Price target lowered to $81 (20% upside) from $88.
    • Raptor Pharmaceutical (RPTP -1.8%) downgraded to Underperform from Perform with an $8 (40% downside risk) price target by Oppenheimer.
    • Aetna (AET -3.5%) downgraded to Market Perform from Outperform by FBR Capital Markets. Price target lowered to $120 (6% upside) from $130.
    • Baxter International (BAX -2.3%) downgraded to Neutral from Buy by Bank of America. Price target lowered to $40 (8% upside) from $78.
    | Tue, Jul. 7, 10:50 AM | 2 Comments
  • Wed, Jul. 1, 10:54 AM
    | Wed, Jul. 1, 10:54 AM | 21 Comments
  • Wed, Jun. 24, 12:40 PM
    • Baxter International (BAX +1.6%) initiated with Buy rating and $45 (post Baxalta) price target by Goldman Sachs.
    • UnitedHealth Group (UNH -2%) initiated with Outperform rating and $159 (33% upside) price target by RBC Capital.
    • Esperion Therapeutics (ESPR +2.1%) initiated with Neutral rating and $86 (4% upside) price target (down from $130) by Credit Suisse.
    • Corindus Vascular Robotics (OTCPK:CVRS +0.2%) initiated with Buy rating and $6 (38% upside) price target by Stifel.
    • Perrigo (PRGO -0.1%) initiated with Outperform rating and $246 (30% upside) price target by BMO Capital.
    • Signal Genetics (SGNL +3.8%) initiated with Buy rating and $2.50 (55% upside) price target by Chardan Capital.
    • CASI Pharmaceuticals (CASI +2.8%) initiated with Buy rating and $2.50 (39% upside) price target by HC Wainwright.
    • Eagle Pharmaceuticals (EGRX -0.8%) initiated with Outperform rating and $97 (11% upside) price target by RBC Capital.
    • BioLineRx (BLRX -0.2%) initiated with Outperform rating and $5 (117% upside) price target by JP Morgan.
    • OncoSec Medical (ONCS -2.5%) initiated with Buy rating and $25 (255% upside) price target by HC Wainwright.
    • Ignyta (RXDX +1.4%) initiated with Overweight rating and $34 (103% upside) price target by Piper Jaffray.
    • Acadia Healthcare (ACHC -1.6%) initiated with Buy rating and $84 (11% upside) price target by Mizuho Securities.
    • Pacira Pharmaceuticals (PCRX -6.2%) initiated with Market Perform rating and $86 (23% upside) price target by Leerink Swann.
    | Wed, Jun. 24, 12:40 PM | Comment!
  • Mon, Jun. 22, 7:48 AM
    • Kamada (NASDAQ:KMDA) collaborates with Baxter (NYSE:BAX) subsidiary Baxalta on a Phase 1/2 clinical trial evaluating Kamada's proprietary alpha-1 antitrypsin (AAT) for the prevention of lung transplant rejection.
    • Under the terms of the agreement, Baxalta will assist in the development of the study as well as the funding. The trial is expected to commence in H1 2016.
    • Kamada's AAT demonstrated positive results in a proof-of-concept Phase 2 study in Graft-versus-Host-Disease conducted with Baxalta.
    • Baxalta has distribution rights to AAT, branded as Glassia, for all indications in the U.S., Canada, Australia and New Zealand. Kamada retains full rights in all other territories.
    • Baxalta will begin trading as a separate company on July 1 under the symbol "BXLT."
    | Mon, Jun. 22, 7:48 AM | Comment!
  • Fri, Jun. 19, 8:28 AM
    • Baxter International (NYSE:BAX) subsidiary Baxalta prices a $5B private offering of senior notes with yields ranging from 2.00% to 5.25%, with one floating rate tranche ($375M). Net proceeds will be used to make a $4B cash distribution to Baxter and for general corporate purposes, including acquisitions.
    • Baxter will use the cash to redeem certain outstanding debt.
    • Baxalta will be spun out by the end of the month. Shares will begin trading on the NYSE under the symbol "BXLT" on July 1.
    | Fri, Jun. 19, 8:28 AM | 2 Comments
  • Fri, Jun. 5, 4:45 PM
    • Baxter International's (NYSE:BAX) Board of Directors approves the separation of its biopharmaceuticals business, known as Baxalta, and declares a special dividend distribution of 80.5% of Baxalta's common stock to Baxter shareholders who will receive one share of Baxalta for each BAX share owned. Baxter will retain a 19.5% stake.
    • Baxalta will begin trading as an independent company on the New York Stock Exchange on July 1 under the symbol "BXLT."
    | Fri, Jun. 5, 4:45 PM | 26 Comments
  • Mon, Jun. 1, 10:13 AM
    • CTI BioPharma (CTIC +17.5%) jumps in early trading in response to its announcement at ASCO (abstract #LBA7006) that patients with myelofibrosis treated with its lead product candidate, pacritinib, in a Phase 3 trial called PERSIST-1 met the primary efficacy endpoint of a statistically significant reduction in spleen volume compared to baseline at week 24. The results were originally reported in March.
    • Fast Track-designated pacritinib, an oral tyrosine kinase inhibitor, is being co-developed with Baxter International (BAX -0.2%). Tyrosine kinase is an enzyme that serves as an "on/off" switch in many cellular functions. If stuck in the "on" position, unregulated cell growth occurs.
    • Previously: CTI Bio up 19% premarket on Phase 3 results (March 9)
    | Mon, Jun. 1, 10:13 AM | 8 Comments
  • Thu, May 21, 11:18 AM
    • Under the decentralized procedure, Baxter International (BAX -0.7%) submits a marketing authorization application to 17 authorities in Europe seeking approval of its 20% concentration subcutaneous immune globulin treatment for patients with primary immunodeficiencies. The company is advancing the 20% product in an effort to expand its treatment portfolio in primary immunodeficiencies.
    | Thu, May 21, 11:18 AM | Comment!
Visit Seeking Alpha's
BAX vs. ETF Alternatives
Company Description
Baxter International Inc is a healthcare company. It develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic conditions.